Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

In the last two years, clinical trials with blocking antibodies to the negative checkpoint regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple negative checkpoint regulators protect the host against autoimmune reactions but also restrict the ability of T cells to ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Mercier, Isabelle, Lines, J. Louise, Noelle, Randolph J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544156/
https://www.ncbi.nlm.nih.gov/pubmed/26347741
http://dx.doi.org/10.3389/fimmu.2015.00418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544156/
https://www.ncbi.nlm.nih.gov/pubmed/26347741
http://dx.doi.org/10.3389/fimmu.2015.00418

Ejemplares similares